Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has ...

For the biotech formerly known as Eliem Therapeutics, it’s all about the climb—Climb Bio, that is. | For the biotech formerly ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly ...

Real Chemistry has partnered with Corval to add a commercialization planning and launch platform to its offering. The ...